Sage Journals: Discover world-class research

Abstract

Background:

MicroRNAs (miRNAs) are short, noncoding RNAs with gene regulatory functions whose expression profiles may serve as disease biomarkers.

Objective:

The objective of this study was to perform a comprehensive analysis of miRNA expression profiles in blood of patients with a clinically isolated syndrome (CIS) or relapsing–remitting multiple sclerosis (RRMS) including next-generation sequencing (NGS).

Methods:

miRNA expression was analyzed in whole blood samples from treatment-naïve patients with CIS (n = 25) or RRMS (n = 25) and 50 healthy controls by NGS, microarray analysis, and quantitative real-time polymerase chain reaction (qRT-PCR).

Results:

In patients with CIS/RRMS, NGS and microarray analysis identified 38 and eight significantly deregulated miRNAs, respectively. Three of these miRNAs were found to be significantly up- (hsa-miR-16-2-3p) or downregulated (hsa-miR-20a-5p, hsa-miR-7-1-3p) by both methods. Another five of the miRNAs significantly deregulated in the NGS screen showed the same direction of regulation in the microarray analysis. qRT-PCR confirmed the direction of regulation for all eight and was significant for three miRNAs.

Conclusions:

This study identifies a set of miRNAs deregulated in CIS/RRMS and reconfirms the previously reported underexpression of hsa-miR-20a-5p in MS. hsa-miR-20a-5p and the other validated miRNAs may represent promising candidates for future evaluation as biomarkers for MS and could be of relevance in the pathophysiology of this disease.

Keywords

Multiple sclerosis clinically isolated syndrome microRNAs biomarker next-generation sequencing microarray real-time polymerase chain reaction

Get full access to this article

View all access options for this article.

References

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–846.

McDonald

Compston

Edan

. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

Miller

Weinshenker

Filippi

. Differential diagnosis of suspected multiple sclerosis: A consensus approach. Mult Scler 2008; 14: 1157–1174.

Bielekova

Martin

. Development of biomarkers in multiple sclerosis. Brain 2004; 127: 1463–1478.

Lewis

Burge

Bartel

. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15–20.

Kozomara

Griffiths-Jones

. miRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39: D152–D157.

Xiao

Rajewsky

. MicroRNA control in the immune system: Basic principles. Cell 2009; 136: 26–36.

Kosik

. The neuronal microRNA system. Nat Rev Neurosci 2006; 7: 911–920.

10.

Chen

. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997–1006.

11.

Keller

Leidinger

Bauer

. Toward the blood-borne miRNome of human diseases. Nat Methods 2011; 8: 841–843.

12.

Mitchell

Parkin

Kroh

. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513–10518.

13.

Siegel

Mackenzie

Chaplin

. Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep 2012; 39: 6219–6225.

14.

Liu

Kang

. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 2009; 10: 1252–1259.

15.

Lindberg

Hoffmann

Mehling

. Altered expression of miR-17–5p in CD4+ lymphocytes of relapsing–remitting multiple sclerosis patients. Eur J Immunol 2010; 40: 888–898.

16.

Otaegui

Baranzini

Armañanzas

. Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One 2009; 4: e6309.

17.

Keller

Leidinger

Lange

. Multiple sclerosis: MicroRNA expression profiles accurately differentiate patients with relapsing–remitting disease from healthy controls. PLoS One 2009; 4: e7440.

18.

De Santis

Ferracin

Biondani

. Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol 2010; 226: 165–171.

19.

Cox

Cairns

Gandhi

. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS One 2010; 5: e12132.

20.

Guerau-de-Arellano

Smith

Godlewski

. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 2011; 134: 3578–3589.

21.

Fenoglio

Cantoni

De Riz

. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett 2011; 504: 9–12.

22.

Lorenzi

Brum

Zanette

. miR-15a and 16-1 are downregulated in CD4(+) T cells of multiple sclerosis relapsing patients. Int J Neurosci 2012; 122: 466–471.

23.

Paraboschi

Solda

Gemmati

. Genetic association and altered gene expression of mir-155 in multiple sclerosis patients. Int J Mol Sci 2011; 12: 8695–8712.

24.

Martinelli-Boneschi

Fenoglio

Brambilla

. MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett 2012; 508: 4–8.

25.

Waschbisch

Atiya

Linker

. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One 2011; 6: e24604.

26.

Junker

Hohlfeld

Meinl

. The emerging role of microRNAs in multiple sclerosis. Nat Rev Neurol 2010; 7: 56–59.

27.

Guerau-de-Arellano

Alder

Ozer

. miRNA profiling for biomarker discovery in multiple sclerosis: From microarray to deep sequencing. J Neuroimmunol 2012; 248: 32–39.

28.

Keller

Backes

Leidinger

. Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients. Mol Biosyst 2011; 7: 3187–3199.

29.

Friedlander

Mackowiak

. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res 2012; 40: 37–52.

30.

Leidinger

Keller

Backes

. MicroRNA expression changes after lung cancer resection: A follow-up study. RNA Biol 2012; 9: 900–910.

31.

Livak

Schmittgen

TD.

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402–408.

32.

Leonhardt

Grundmann

Behe

. Inflammatory neovascularization during graft-versus-host disease is regulated by alphav integrin and miR-100. Blood 2013; 121: 3307–3318.

33.

Sun

Lin

Chen

YQ.

Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol 2013; 6: 6.

34.

Junker

Krumbholz

Eisele

. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 2009; 132: 3342–3352.

35.

Angerstein

Hecker

Paap

. Integration of microRNA databases to study microRNAs associated with multiple sclerosis. Mol Neurobiol 2012; 45: 520–535.

36.

Santiago-Raber

Lawson

Dummer

. Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J Immunol 2001; 167: 4067–4074.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB

0.49 MB

Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing

Abstract

Background:

Objective:

Methods:

Results:

Conclusions:

Keywords

Get full access to this article

References

Supplementary Material